HEALTH

CAMBRIDGE, Mass. — Results from a new survey released Monday of 5,256 PatientsLikeMe members who live day to day with life-changing conditions found that nearly one-third of respondents never (5%) or rarely (25%) get a good night’s sleep. Nearly half (44%) wake up a lot during the night every night, or almost every night.

The survey also found that sleep problems for the group are chronic, with more than half (53%) saying their sleep problems have lasted for more than a year. 

DENVER — MusclePharm on Monday announced that its Arnold Series, a new line of nutritional supplements developed by Arnold Schwarzenegger, will launch today on GNC.com and on Oct. 1, in GNC stores.

MEMPHIS, Tenn. — St. Jude Children's Research Hospital is applauding the retailers that have joined and returned to its annual campaign to raise money for children's cancer research.

WASHINGTON — Use of specific dietary supplements in targeted populations not only provides health benefits, but also, according to a new economic report released Monday, offers significant savings for healthcare costs. 

DORNSTETTEN, Germany — The family-owned Schupp GmbH and Co. KG company has just developed and launched a new type of kinesiology tape, the company announced today.

CAMPTON, Ky. — Chuck Woolery, TV personality and game show host, has recently acquired a minority stake in Nature’s Health Connection, Inc., the makers of Australian Dream Arthritis Pain Relief Cream.

Mr. Woolery, who has recently appeared as a spokesperson in a radio commercial campaign for the pain relief cream, began using Australian Dream to treat his own minor arthritis pain. Mr. Woolery was so satisfied by the results he experienced with product, he decided to invest in the company.

HAWTHORNE, N.Y. — Taro Pharmaceutical Industries reported last week that it has received approval from the Food and Drug Administration for its new drug application Topicort (desoximetasone) topical spray, 0.25%.

Topicort topical spray, 0.25% is a corticosteroid indicated for the treatment of plaque psoriasis in patients 18 years of age or older.

According to Taro, the corticosteroid spray market is approximately $100 million in annual sales in the United States.

Does the Obama administration “get it” when it comes to pharmacy’s vital interests and lowering healthcare costs?

One sometimes wonders. As much as I like the president and many of his ideas and instincts, I’m sometimes stumped by some of the lesser-understood facets of the administration’s health policy, and by the seemingly contradictory sets of priorities promoted by that policy.